Anitoa Unveils Ultra-portable qPCR System at Molecular Med Tri-con 2018

MENLO PARK, Calif., Feb. 13, 2018 /PRNewswire/ -- Anitoa Systems, LLC, a Menlo Park, California-based medical device company, today introduces Maverick, an ultra-portable quantitative-polymerase-chain-reaction (qPCR) system. At less than 1 kilo-gram in a handheld format, Maverick is created to facilitate point-of-care molecular testing for both medical and non-medical applications.

Maverick is packed with technology innovations from Anitoa, a young Silicon Valley medical device company. These innovations include a unique proprietary low-light sensitive, complementary metal-oxide-semiconductor (CMOS) 4-channel fluorescence optics system that allows fast and highly multiplexed DNA detection without the need for field calibration. Maverick is further enhanced with a cloud-based software that is seamlessly connected to the Internet, and enables cloud data storage and retrieval. Maverick software also includes a machine learning technology-ready data analytics engine.

Applications of Maverick include near-patient diagnostics, food, agriculture and environment testing, forensics, and basic biological research. Anitoa has previously demonstrated Maverick technology in detecting several types of pathogen DNA and RNA strands, such as Hepatitis B and C, HIV, E. coli and many of their drug-resistant variants. Maverick has been shown to achieve reliable detection of only 4 copies pathogen molecule DNA per sample with over 9 orders of magnitude in dynamic range.

"We are excited to bring to the market a portable qPCR device with performance that rivals the most expensive lab-based systems, at a fraction of the cost," said Dr. Zhimin Ding, CEO of Anitoa Systems. "We strive to make our molecular testing systems rugged, accessible, and with battery operation and power-loss protection capability to facilitate their effective use in low resource settings."

Availability

Maverick is available now for evaluation through Anitoa's early access program (EAP). Commercial release of Maverick is planned for Q3, 2018. For details of Anitoa's EAP program, please contact Anitoa Systems at [email protected].

About Anitoa

Anitoa Systems, a medical device technology start-up established in 2013 with headquarter in Menlo Park, California, develops highly-integrated and low-power CMOS-based bio-sensor devices for fluorescence and chemiluminescence-based molecular imaging. By replacing the traditional bulky and costly photon-multiplier tube (PMT) and CCD-based optical sub-systems, Anitoa's ultra-low-light CMOS sensor technology enables a new generation of compact and inexpensive molecular testing platforms targeting infectious diseases and cardio-vascular diseases. Anitoa partners with Zhejiang Nano-systems Institute (ZCNI), and the First Affiliated Hospital of Zhejiang University in China for clinical validation and field deployment. For further information please contact: Sales & PR Contact: Yuping Chung, Anitoa Systems, LLC, [email protected] or 408-887-6026. www.anitoa.com

SOURCE Anitoa Systems, LLC